Chelation Therapy and Heart Disease: What the TACT Trials Found
A balanced review of the TACT and TACT2 trials of EDTA chelation for cardiovascular disease, including their limitations and current clinical implications.
On This Page
EDTA chelation has been studied as a possible cardiovascular treatment, but it remains uncertain and is not part of routine evidence-based heart care. The two major NIH-funded trials—TACT and TACT2—produced different results. Reading them together is important because the later trial was designed to test whether the most promising earlier finding could be repeated.
The Original TACT Trial
The Trial to Assess Chelation Therapy (TACT) enrolled 1,708 adults who had previously experienced a myocardial infarction. Participants received either an EDTA-based infusion regimen or placebo in addition to their existing cardiovascular care.1
TACT reported a modest reduction in its composite primary endpoint, which combined death, recurrent heart attack, stroke, coronary revascularization and hospitalization for angina. A prespecified subgroup analysis suggested a larger association among participants with diabetes.1,2 Subgroup findings can generate useful research questions, but they do not by themselves establish that a treatment works for that population.
What TACT2 Found
TACT2 was designed to examine the diabetes subgroup finding more directly. It enrolled 959 participants with diabetes and a previous heart attack. Although EDTA increased urinary lead excretion, the primary cardiovascular outcome occurred at the same rate in the chelation and placebo groups. The investigators concluded that the results did not support EDTA chelation to reduce cardiovascular events in this population.3
TACT2 therefore did not confirm the cardiovascular benefit suggested by TACT. Explanations proposed for the different results remain hypotheses and should not be presented as proof that chelation works in another population.
Toxic Metals and Cardiovascular Risk
Lead, cadmium and arsenic exposure are associated with cardiovascular risk, and reducing environmental exposure is an important public-health goal.4 However, an association between metal exposure and cardiovascular disease does not establish that chelation improves cardiovascular outcomes.
When a specific exposure is suspected, assessment should be based on the exposure history and validated testing appropriate to that metal. Post-chelator or “provoked” urine testing is not recommended: chelating agents predictably increase urinary metal excretion, and validated reference ranges are not available for interpreting those results.
Confirmed clinically significant metal poisoning is a separate indication from cardiovascular prevention. It requires management based on the particular metal, measured level, symptoms, organ function and appropriate medical or poison-control guidance.
Risks and Limitations
EDTA chelation is an invasive treatment with potential risks. These include IV-site complications, changes in blood pressure, kidney injury, mineral or electrolyte disturbances, reactions to ingredients and complications from an inappropriate dose or infusion rate. Risks vary with the chelating agent, formulation and the person’s health.
No website can determine whether chelation is appropriate or provide a treatment schedule. A clinical assessment must first establish a supportable indication, consider alternatives and review the expected benefits, uncertainty, risks and costs. Cardiovascular symptoms or known heart disease require appropriate medical assessment and should not be managed through chelation in place of established care.
Current Practical Conclusion
The combined TACT evidence does not support advertising EDTA chelation as a proven treatment for heart disease or as a way to reduce cardiovascular events. Its established role is limited to selected cases of confirmed metal poisoning under appropriate clinical oversight—not nonspecific symptoms, unvalidated testing or general cardiovascular risk.
If you are concerned about a specific metal exposure, an initial consultation can review the history and whether validated testing or referral is appropriate. An assessment does not mean that chelation will be recommended.
References
- Lamas GA, Goertz C, Boineau R, et al. Effect of an EDTA-based chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-1250.
- Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in TACT. Circ Cardiovasc Qual Outcomes. 2014;7(1):15-24.
- Lamas GA, et al. Edetate disodium-based chelation for patients with a previous myocardial infarction and diabetes: TACT2. JAMA. 2024.
- Lamas GA, Bhatnagar A, Jones MR, et al. Contaminant metals as cardiovascular risk factors: a scientific statement from the American Heart Association. J Am Heart Assoc. 2023;12(13):e029852.
Frequently Asked Questions
Is chelation therapy a replacement for conventional heart treatment?
No. EDTA chelation has not been established as a replacement for evidence-based medications, procedures, rehabilitation or risk-factor management. People with cardiovascular disease should continue care with their physician or cardiologist.
Did the TACT trials prove that chelation prevents cardiovascular events?
No. The original TACT trial reported a modest signal in a composite outcome, but its confirmatory successor, TACT2, found no reduction in cardiovascular events. The total evidence does not establish routine EDTA chelation as cardiovascular treatment.
How is suspected metal exposure assessed?
Testing depends on the metal and exposure history and generally uses validated blood or non-provoked urine tests. Post-chelator or “provoked” urine testing is not recommended for diagnosing metal toxicity.